Project Grant W81XWH2110010

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI, CFDA 93.837 Cardiovascular Diseases Research) provides $704,795 to Baylor College of Medicine to develop a cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The researchers are engineering retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines IL-1RA and IL-10 for local delivery to the lungs. They will develop...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $186,408 to the University of Washington to examine the use of the monoclonal antibody IC14 as a potential treatment for Acute Respiratory Distress Syndrome (ARDS). The award aims to: (1) analyze blood leukocyte data to determine the effects of IC14 on cellular targets, (2) evaluate the relationship between the biomarker presepsin...

The Icahn School of Medicine at Mount Sinai will receive $329,997 under a Project Grant award from the Defense Health Agency to develop an antibody treatment for SARS-CoV-2, the virus that causes COVID-19. The award period is from January 15, 2021 through January 14, 2024. The grant will support research to develop an antibody targeting TMPRSS2 as an antiviral treatment for COVID-19. This work aligns with the goals of the Military Medical Research and Development program administered by the...

The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), has awarded a $300,000 Project Grant to Biotherapeutics, Inc., a biotech company located in Blacksburg, Virginia. The grant aims to accelerate the development of Biotherapeutics' novel, oral, first-in-class immunoregulatory therapeutic for the treatment of Clostridioides difficile infection (CDI). The specific objectives of this SBIR Phase I grant are to:...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $391,250.00 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding supports a 3-year research project to investigate the role of the fibrinogen protein as a mediator of COVID-19-associated coagulopathy (abnormal blood clotting). Specifically, the research aims to: 1) Define the impact of therapeutic plasma exchange (TPE) on blood rheology and vascular integrity in COVID-19...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,504,820.00 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University in Indianapolis to conduct research on the chronic lung disease and immune responses observed in patients following acute COVID-19 infection. The key objectives of the project are to: 1) obtain bronchoalveolar lavage (BAL) samples and peripheral blood from patients with persistent lung disease after COVID-19 for...

This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $842,408 to support the development and evaluation of the Aerosolve Biohelmet. The Aerosolve Biohelmet is a personal negative pressure device designed to rapidly isolate and safely transport patients with highly transmissible respiratory illnesses like COVID-19, influenza, and tuberculosis. The...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $408,606 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oklahoma State University (OSU) to conduct research on the role of ERK1/2 signaling in SARS-CoV-2-induced dysregulated immunity and lung pathology. The primary objective of the 5-year study, which runs from September 2024 to June 2029, is to demonstrate the critical role of myeloid cell toll-like receptor (TLR)-ERK1/2 signaling in...

The Department of the Army Medical Command awarded a $1,093,692.71 Project Grant to HMH Hospitals Corporation, doing business as Hackensack University Medical Center, to support a randomized clinical study of convalescent plasma from recovered COVID-19 donors collected through plasmapheresis as treatment for early COVID-19 infection. The study aims to evaluate the safety and efficacy of convalescent plasma as a treatment option for COVID-19 under the Military Medical Research and Development...